Astellas Says Full-Year Profit Rose 16% Vesicare Sales

Astellas Pharma Inc. (4503), Japan’s third-largest drugmaker, said full-year profit rose 16 percent, led by higher sales of urinary disorder treatment Vesicare.

Net income rose to 78.2 billion yen ($981 million), or 169.4 yen a share, in the 12 months ended March from 67.7 billion yen, or 146.5 yen a share, a year earlier, Tokyo-based Astellas said in a statement today. Profit was expected to rise to 87.6 billion yen, according to the average of 14 analyst estimates compiled by Bloomberg.

To contact the reporter on this story: Kanoko Matsuyama in Tokyo at kmatsuyama2@bloomberg.net.

To contact the editor responsible for this story: Jason Gale in Melbourne at j.gale@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.